Global In-Vitro Fertilization (IVF) market is expected to reach
USD 27 billion by 2022, according to a new report by Grand View Research, Inc.
The market is driven by the increasing incidence of infertility owing to,
lifestyle changes, expansion of fertility procedures for treating male
infertility such as ICSI, government initiatives to provide better
reimbursement policies, and continuous efforts by the industry
contributors.
Moreover, the availability of
genomic testing enabling the prevention of the transfer of genetic disease
during IVF use is further expected to drive the market demand. The increase in
the number of IVF treatment has led more insurance players to cover the IVF
procedures. This has ultimately led to competitive pricing and has moderated
the treatment costs as IVF has been a successfully practiced technology. This
will most likely drive the market by introducing treatment standardization and
automation.
The behavioral shift in the
society is a major factor contributing to the decreased Total Fertility Rate
(TFR). These factors include an increasing number of women in the labor force,
the increased age of the first birth, a shift from rural to urban societies,
lower marriage rates, postponement of marriage, and greater levels of education
for women.
Obesity is another factor,
which has led to an increase in infertility in the population. This is due to
the fact that the fat deposited on women’s abdomen prevents follicular
stimulation and produces male hormones. In the case of males, the rising fat
decreases testosterone levels causing a problem in sperm production. Doctors
have started recommending weight loss in men prior to fertility treatments
along with proper Body Mass Index (BMI) maintenance. The U.S. Endocrine Society
has established the use of Letrozole to increase the testosterone levels in
obese patients.
Request to Sample of
This Report @ http://www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market
Further key findings
from the report suggest:
·
Intracytoplasmic
Sperm Injection (ICSI) dominated the market in 2014.ICSI was introduced in the
year 1992 and boosted the fertility rates from 50% to 80%, according to the
American Society for Reproductive Medicine. In April 2016, Nigeria recorded its
first successful delivery from a frozen egg. Bridge Clinic has stored the eggs
using the flash-freezing technique. With this birth, Nigeria has put itself on
the global map as it now offers IVF through frozen eggs. The eggs were then
fertilized using the ICSI technique.
·
Frozen Embryo
Replacement (FER) technique is expected to witness a rapid rise in demand.
Conventionally, most embryos were transferred through fresh cycles. However,
with technology refinement, the number of frozen embryo transfers and the
success rates have increased. Moreover, the policy of freezing the embryos has
also reduced the chances of ovarian hyper-stimulation. The frozen embryo
transfers enable single egg transfer, thus, giving enough time for the
endometrial layer to heal from the medicine stimulation effect. This ensures
higher success rates.
·
Culture media
dominated the overall market in terms of revenue in 2014. With the increasing
government funding and industrial support for employees for egg/sperm freezing,
the demand for cryopreservation and the needed media for it is expected to
witness growth. There has been an increase in the research activities
undertaken to improve the culture media and to procure maximum boar sperms or
eggs, spurring market growth. Moreover, the increasing number of egg/sperm
donor banks is expected to drive the demand for sperm, egg, and embryo
processing media during the forecast period.
·
Europe dominated
the IVF market in 2014. High quality of treatment offered at the most
economical price, and the adherence to medical standards have contributed to
its market leadership. In Europe, the NHS covers three IVF cycles and has also
started providing coverage for gametes freezing. Moreover, the region is an
attraction for international clients as countries, such as Spain, have the
highest number of egg donors. The clinics also provide sex identification and
other IVF treatments, which are not offered in North America.
·
North America
also accounted for a significant share of the market in 2014. The
standardization of procedures through automation, regulatory reforms,
government funding for egg/sperm storage, and industry players introducing more
IVF treatments are some contributing factors for North America dominating the
IVF market.
·
The presence of
favorable reimbursement framework (implementation of USD 50 million 5-year
plans by the U.S Department of Defense for sperm/egg freezing coverage) is also
expected to drive regional market growth over the next six years. The
increasing number of clinics undertaking newer industrial techniques to offer
better fertility success rates is also expected to boost the regional market
demand.
·
The demand for
IVF treatment is expected to boom in APAC owing to fertility tourism,
increasing foreign industries trying to penetrate the economically developing
countries and the changing regulatory landscape.
·
The Asia Pacific
Initiative on Reproduction (ASPIRE), the task force of clinicians and
scientists is involved in the monitoring and management of fertility and
Assisted Reproductive Technology (ART). Such initiatives promote awareness
levels thereby, driving growth.
·
Industry
contributors are introducing newer automation to shift the IVF treatment from
invasive to a minimally invasive or non-invasive procedure. The industry
players are also trying technologies, which can enable older women to have
enhanced fertility rates. For instance, in August 2015, OvaScience announced
the results of its first published analysis comparing AUGMENT fertility
treatment with a standard IVF. The results showed a significantly higher rate
of selection and transfer of embryos as compared to the standard
treatment.
·
Some key players
in this market includeEMD Serono Inc., Boston IVF, OvaScience, Thermo Fisher
Scientific Inc., Vitrolife AB, Irvine Scientific, CooperSurgical, Inc., Cook
Medical Inc., Genea Biomedx and Progyny Inc.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/in-vitro-fertilization-market/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment